<DOC>
	<DOC>NCT00510159</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of praziquantel versus As+SMP (Co-Arinate FDC Â®) in the treatment of Schistosoma haematobium in 6-15 year old Malian children. The nul-hypothesis in this study is that the combination of As+SMP is more effective than praziquantel in the treatment of S. haematobium infected children.</brief_summary>
	<brief_title>Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis</brief_title>
	<detailed_description />
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Sulfalene</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<criteria>Aged between 615 years In good health, according to study doctor Suffering from urinary schistosomiasis, as diagnosed by the presence of S. haematobium eggs in the urine. Residents of Djalakorodji Capable of taking oral medication Written informed consent to participate in the study, obtained from parent or legal guardian. Weighing more than 50 kg Being pregnant or lactating at the time of the study Patient has a severe concomitant disease, as determined by the clinical examination, such as cerebral cysticercosis, HIV,... Signs of severe malnutrition (children weighing/measuring more than 3 standard deviations or less than 70% of the median standard reference values determined by WHO, or with systemic oedema affecting both feet). Hypersensitivity to As, SMP or PZQ Having taken other antimalarial or antischistosomal medication during the study. Having participated in previous similar studies</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Schistosoma haematobium</keyword>
	<keyword>Praziquantel</keyword>
	<keyword>Artesunate + Sulfamethoxypyrazine/pyrimethamine</keyword>
	<keyword>Randomized double blind placebo controlled clinical trial</keyword>
</DOC>